Figure 4From: Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trialAntigen-Specific Lymphocyte Proliferation. The proliferative response was determined by3H-thymidine incorporation (DPM). Data plotted as the relative change from pre-vaccination baseline. Stars are indicated the statistical significance (*p < 0.05; **p < 0.001) comparing pre (White bar) vs. post-vaccination (Black bar).Back to article page